ChromaDex Future Growth

Future criteria checks 4/6

ChromaDex is forecast to grow earnings and revenue by 93.2% and 15.4% per annum respectively while EPS is expected to grow by 101.2% per annum.

Key information

93.2%

Earnings growth rate

101.2%

EPS growth rate

Life Sciences earnings growth	15.9%
Revenue growth rate	15.4%
Future return on equity	n/a
Analyst coverage	Low
Last updated	09 Apr 2024

Recent future growth updates

Recent updates

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Apr 05

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

Feb 28

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Jan 29

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

Jun 08

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Mar 31

ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé

Oct 11

ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent

Aug 15

Some ChromaDex Corporation (NASDAQ:CDXC) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 15

We're Not Very Worried About ChromaDex's (NASDAQ:CDXC) Cash Burn Rate

Mar 03

Companies Like ChromaDex (NASDAQ:CDXC) Can Afford To Invest In Growth

Nov 19

When Should You Buy ChromaDex Corporation (NASDAQ:CDXC)?

Sep 14

We Discuss Whether ChromaDex Corporation's (NASDAQ:CDXC) CEO Is Due For A Pay Rise

Jun 11

ChromaDex to sell Tru Niagen in 3,800 Walmart stores in the U.S.

Jun 07

Is There Now An Opportunity In ChromaDex Corporation (NASDAQ:CDXC)?

Jun 02

We Think ChromaDex (NASDAQ:CDXC) Can Easily Afford To Drive Business Growth

May 14

Earnings and Revenue Growth Forecasts

NasdaqCM:CDXC - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	138	9	13	14	1
12/31/2025	114	4	9	14	4
12/31/2024	97	-2	1	6	5
12/31/2023	84	-5	7	7	N/A
9/30/2023	83	-6	6	6	N/A
6/30/2023	81	-6	2	2	N/A
3/31/2023	77	-11	-6	-5	N/A
12/31/2022	72	-17	-15	-15	N/A
9/30/2022	69	-20	-20	-20	N/A
6/30/2022	69	-28	-22	-22	N/A
3/31/2022	70	-27	-26	-26	N/A
12/31/2021	67	-27	-25	-24	N/A
9/30/2021	65	-28	-20	-19	N/A
6/30/2021	62	-23	-17	-17	N/A
3/31/2021	60	-21	-11	-11	N/A
12/31/2020	59	-20	-11	-11	N/A
9/30/2020	57	-23	-12	-11	N/A
6/30/2020	55	-26	-16	-15	N/A
3/31/2020	51	-30	-23	-23	N/A
12/31/2019	46	-32	-21	-20	N/A
9/30/2019	42	-32	-26	-25	N/A
6/30/2019	38	-33	-23	-22	N/A
3/31/2019	35	-33	-22	-20	N/A
12/31/2018	32	-33	-22	-21	N/A
9/30/2018	30	-34	-21	-20	N/A
6/30/2018	28	-29	-17	-15	N/A
3/31/2018	24	-23	-15	-14	N/A
12/30/2017	21	-17	N/A	-10	N/A
9/30/2017	18	-10	N/A	-6	N/A
7/1/2017	16	-8	N/A	-6	N/A
4/1/2017	18	-6	N/A	0	N/A
12/31/2016	22	-4	N/A	-3	N/A
10/1/2016	22	-3	N/A	-4	N/A
7/2/2016	24	-2	N/A	-5	N/A
4/2/2016	24	-1	N/A	-4	N/A
1/2/2016	18	-3	N/A	-2	N/A
10/3/2015	22	-3	N/A	-2	N/A
7/4/2015	20	-3	N/A	-1	N/A
4/4/2015	18	-5	N/A	-2	N/A
1/3/2015	15	-5	N/A	-3	N/A
9/27/2014	13	-5	N/A	-4	N/A
6/28/2014	12	-5	N/A	-4	N/A
3/29/2014	11	-5	N/A	-5	N/A
12/28/2013	10	-4	N/A	-4	N/A
9/28/2013	11	-5	N/A	-3	N/A
6/29/2013	12	-6	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CDXC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: CDXC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CDXC is expected to become profitable in the next 3 years.

Revenue vs Market: CDXC's revenue (15.4% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: CDXC's revenue (15.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CDXC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

ChromaDex Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus EPS estimates have been upgraded.

Price target increased by 13% to US$5.53

Price target decreased by 9.3% to US$4.94

Consensus EPS estimates upgraded to US$0.088 loss

ChromaDex Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 11% to US$4.88

Recent updates

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

New minor risk - Share price stability

Consensus EPS estimates have been upgraded.

Price target increased by 13% to US$5.53

Price target decreased by 9.3% to US$4.94

Full year 2023 earnings: EPS exceeds analyst expectations

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

ChromaDex Corporation to Report Q4, 2023 Results on Mar 06, 2024

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Neurohacker Collective and Chromadex Partner to Optimize Cellular Health with the Debut of Qualia Nad+

Ch ChromaDex Corp. shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD)

Chromadex Corp. Shares Results from Phase II Clinical Study

Consensus EPS estimates upgraded to US$0.088 loss

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ChromaDex Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 11% to US$4.88

ChromaDex Corp. Debuts Clinical Strength Tru Niagen®? Pro 1,000Mg Featuring Niagen®? (Patented Nicotinamide Riboside)

ChromaDex Corporation to Report Q3, 2023 Results on Nov 08, 2023

ChromaDex Corp. and Zesty Paws Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line

New minor risk - Market cap size

Chromadex Announces Results from Newly Published Clinical Study, as Reported in the Peer-Reviewed Journal Cell Reports, Demonstrating That Supplementation with Nicotinamide Riboside

Consensus EPS estimates upgraded to US$0.12 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ChromaDex Corporation to Report Q2, 2023 Results on Aug 09, 2023

ChromaDex Corp. Announces Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD) in Glaucoma Patients and That Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ChromaDex Corporation Provides Revenue Guidance for the Full Year 2023

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS misses analyst expectations

ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients

ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis

ChromaDex Appoints Dr. Vilhelm Bohr to Its Scientific Advisory Board

Chromadex Corporation Names Brianna Gerber Chief Financial Officer

Forecast to breakeven in 2025

ChromaDex Corporation Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside Increase Nicotinamide Adenine Dinucleotide Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

Chromadex Corp. Reports FDA’S Conclusion That Nicotinamide Mononucleotide (Nmn) May Not Be Sold or Marketed as A Dietary Supplement in the United States

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ChromaDex Corporation Provides Earnings Guidance for the Year 2022

ChromaDex Corporation to Report Q3, 2022 Results on Nov 02, 2022

ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé

Chromadex Shares Promising Findings from Clinical Study Showcasing The Safety and Tolerability of Nicotinamide Riboside (Nr) in Heart Failure with Reduced Ejection Fraction

Insider recently bought US$1.2m worth of stock

ChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock sale

ChromaDex in pact to introduce anti-aging compound in Brazil

Ayana Bio appoints Frank Jaksch as CEO

ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent

Price target decreased to US$6.79

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Chromadex Corporation Announces Executive Changes

ChromaDex Corporation to Report Q2, 2022 Results on Aug 10, 2022

ChromaDex Corporation(NasdaqCM:CDXC) dropped from Russell 2000 Dynamic Index

Less than half of directors are independent

ChromaDex Corporation Announces Directors Changes

Insider recently bought US$100k worth of stock

ChromaDex Corporation Announces Resignation of Frank L. Jaksch, Jr as Executive Director, with Effect from June 30, 2022

Insider recently bought US$52k worth of stock

Consensus EPS estimates fall by 31%

No longer forecast to breakeven

Price target decreased to US$9.86

ChromaDex Corporation Appoints Kristin Patrick and Ann Cohen to Its Board of Directors

ChromaDex Corporation to Report Q1, 2022 Results on May 12, 2022

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

ChromaDex Corporation Announces Board Changes

Caroline Levy Notifies Her Intention to Resign from the Board and as Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board of Chromadex Corporation

Kurt Gustafson Announces Not to Stand for Re-Election as director of Board of Directors of the Company and as a member of the Audit Committee and Compensation Committee of the Board of ChromaDex Corporation